Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Erasca, Inc.
  6. News
  7. Summary
    ERAS   US29479A1088

ERASCA, INC.

(ERAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Guggenheim Adjusts Price Target for Erasca to $20 From $25, Maintains Buy Rating

01/03/2022 | 01:09pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about ERASCA, INC.
05/12Erasca Narrows Q1 Loss, Misses Street Estimates
MT
05/12ERASCA, INC. Management's Discussion and Analysis of Financial Condition and Results o..
AQ
05/12Earnings Flash (ERAS) ERASCA Reports Q1 Loss $-0.31
MT
05/12Erasca Reports First Quarter 2022 Financial Results and Business Updates
GL
05/12Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Erasca to Present at the Bank of America Securities 2022 Healthcare Conference
AQ
04/27ERASCA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/27Erasca Appoints Jean Liu to its Board of Directors
AQ
04/27Erasca Appoints Jean Liu to its Board of Directors
CI
04/12Erasca Says Data Support Clinical Development of Certain Programs
MT
More news
Analyst Recommendations on ERASCA, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -161 M - -
Net cash 2022 275 M - -
P/E ratio 2022 -4,44x
Yield 2022 -
Capitalization 704 M 704 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 123
Free-Float 79,8%
Chart ERASCA, INC.
Duration : Period :
Erasca, Inc. Technical Analysis Chart | ERAS | US29479A1088 | MarketScreener
Technical analysis trends ERASCA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 5,78 $
Average target price 21,60 $
Spread / Average Target 274%
EPS Revisions
Managers and Directors
Jonathan E. Lim Chairman & Chief Executive Officer
David M. Chacko Chief Business Officer
Michael D. Varney Chairman-Research & Development
Wei Lin Chief Medical Officer
Les Brail VP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ERASCA, INC.-62.90%704
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567